Citadel Advisors
UNCY icon

Citadel Advisors’s Unicycive Therapeutics UNCY Stock Holding History

Citadel Advisors’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$693K Buy
147,700
+65,200
+79% +$481K ﹤0.01% 9107
2026
Q1 		$543K Buy
+82,500
New +$541K ﹤0.01% 9097

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Citadel Advisors's UNCY Position: Q2 2026 in Review

Citadel Advisors reduced its Unicycive Therapeutics (UNCY) stake by 74% in Q2 2026, selling an estimated $1.3M and leaving 61,168 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #11213.

Citadel Advisors first reported a position in UNCY in Q1 2022 and has held it in 8 quarters since. The position peaked at $1.56M in Q1 2026. 79 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Citadel Advisors held 61,168 shares of Unicycive Therapeutics worth $287K as of Q2 2026.
  • Citadel Advisors sold 175,673 Unicycive Therapeutics shares in Q2 2026, an estimated $1.3M.
  • Unicycive Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11213 holding.
  • Citadel Advisors first reported a position in Unicycive Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • Citadel Advisors's Unicycive Therapeutics position peaked at $1.56M in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.